Rh Factor: Prevention of Isoimmunization and Clinical Trial on Mothers

See allHide authors and affiliations

Science  18 Feb 1966:
Vol. 151, Issue 3712, pp. 828-830
DOI: 10.1126/science.151.3712.828


The results on the use of γG-immunoglobulin to Rh factor for the prevention of active immunization of Rh-negative mothers at risk appear most promising. One hundred and seven mothers in the clinical trial have been followed for periods of about 6 months to 1½12 years after delivery. Of these, 48 were treated mothers who received 5 ml γG-immunoglobulin to Rh, and 59 were untreated mothers. Of the 48 treated mothers none are actively immunized; seven of the 59 control mothers have become actively immunized to Rh.